TITLE

Efficacy of Anakinra for Various Types of Crystal-Induced Arthritis in Complex Hospitalized Patients: A Case Series and Review of the Literature

AUTHOR(S)
Aouba, A.; Deshayes, S.; Frenzel, L.; Decottignies, A.; Pressiat, C.; Bienvenu, B.; Boue, F.; Damaj, G.; Hermine, O.; Georgin-Lavialle, S.
PUB. DATE
March 2015
SOURCE
Mediators of Inflammation;3/26/2015, Vol. 2015, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background. There are few data on anakinra use after failure of conventional medications for crystal-induced peripheral arthritis and/or crowned dens syndrome among complex hospitalized patients. Methods. We retrospectively analyzed the outcome of six patients affected with subacute crystal-induced arthritis who had received anakinra in second or third line therapy, including three patients with crowned dens syndrome and three others with gouty arthritis. Patients’ comorbidities, reasons for anakinra use and associated drugs, and outcomes were recorded. Results. All patients presented with elevated inflammatory syndrome, systemic symptoms with poly/oligoarthritis. Except for absolute contraindications, all patients were previously treated with full or decreased dose of NSAID, colchicine, and/or glucocorticoids, with unsatisfactory response. All three gouty patients exhibited complete responses in all acute involvements under anakinra within 3 to 5 days, including one of them who needed the reintroduction of colchicine treatment that was previously unsuccessful. Crowned dens syndrome patients, including two with pseudogout and one with subacute hydroxyapatite deposition disease, needed 9 to 11 days to achieve complete response. Tolerance to anakinra was good. Conclusion. In case series of complex hospitalized patients, anakinra showed good activity in crowned dens syndrome and associated crystal-induced peripheral arthritis, with longer treatment duration than in gouty arthritis.
ACCESSION #
109224136

 

Related Articles

  • The role of non-steroidal anti-inflammatory drugs (NSAIDs) after acute exercise-induced muscle injuries. Ho, Andrew M.; Bedair, Hany; Fu, Freddie H.; Huard, Johnny // International SportMed Journal;2004, Vol. 5 Issue 3, p209 

    Objective: To examine the role of non-steroidal anti-inflammatory drugs (NSAIDs) in treating exercise-induced muscle injuries. Data sources: Electronic databases MEDLINE, PreMEDLINE, and SPORTDiscus were searched for articles published between 1966 and 2004 using the keywords "NSAID AND exercise...

  • Preoperative topical NSAID yields improved phaco efficiency. Groves, Nancy // Ophthalmology Times;7/1/2005, Vol. 30 Issue 13, p16 

    Describes the results of the introduction of a topical nonsteroidal anti-inflammatory drug before phacoemulsification in terms of surgical efficacy and outcomes at the American Society of Cataract and Refractive Surgery annual meeting in the U.S. Evaluation on the pharmacokinetic response curve...

  • Underreported use of non-steroidal anti-inflammatory drugs in an outpatient gastroenterology practice: a prospective office-based survey. Majithia, Raj; Johnson, David A.; Ryan, Michael J.; Wootton, F. Taylor; Willis, Jeff; Hornbuckle, Kelvin; Brooks, Whitney // Gastroenterology Insights;2013, Vol. 5 Issue 1, p9 

    Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most commonly used class of medications worldwide. It is estimated that more than 20 million people take NSAIDs daily. We examined the underreported use of NSAIDs on a standardized office intake assessment questionnaire of patient...

  • Study confirms impact of OCs on dysmenorrhea.  // Contraceptive Technology Update;Apr2012, Vol. 33 Issue 4, p46 

    The article reports on Scandinavian research which found that combined oral contraceptives alleviate the symptoms of dysmenorrhea and painful menstrual periods.

  • Chronic musculoskeletal conditions and comorbidities in primary care settings. Hudon, Catherine; Fortin, Martin; Soubhi, Hassan // Canadian Family Physician;Jan2008, Vol. 54 Issue 1, p74 

    OBJECTIVE To estimate the prevalence of chronic musculoskeletal conditions in primary care. Among patients with these conditions, to estimate the mean number of comorbidities and the prevalence of chronic diseases that could deteriorate with use of nonsteroidal anti-inflammatory drugs (NSAIDs)....

  • Direct medical costs associated with rheumatoid arthritis in Turkey: analysis from National Claims Database. Baser, Onur; Burkan, Abdulkadir; Baser, Erdem; Koselerli, Rasim; Ertugay, Emre; Altinbas, Akif // Rheumatology International;Oct2013, Vol. 33 Issue 10, p2577 

    This study aimed to estimate and identify determinants of direct medical costs associated with rheumatoid arthritis (RA) in Turkey using nationwide real-world data. Using the Turkish National Health Insurance Database (2009-2011), RA patients (ages 18-99) were identified using International...

  • Cardiovascular risk with non-steroidal anti-inflammatory drugs: clinical implications. Bello, Alfonso E; Holt, Robert J // Drug Safety;Nov2014, Vol. 37 Issue 11, p897 

    In February 2014, the US Food and Drug Administration (FDA) convened an advisory committee meeting to discuss the accumulated data relating to the cardiovascular risk of non-steroidal anti-inflammatory drugs (NSAIDs) and the potential implications on the class prescription labeling. The...

  • Effect of analgesic therapy on clinical outcome measures in a randomized controlled trial using client-owned dogs with hip osteoarthritis. Malek, Sarah; Sample, Susannah J.; Schwartz, Zeev; Nemke, Brett; Jacobson, Peer B.; Cozzi, Elizabeth M.; Schaefer, Susan L.; Bleedorn, Jason A.; Holzman, Gerianne; Muir, Peter // BMC Veterinary Research;2012, Vol. 8 Issue 1, p185 

    Background: Pain and impaired mobility because of osteoarthritis (OA) is common in dogs and humans. Efficacy studies of analgesic drug treatment of dogs with naturally occurring OA may be challenging, as a caregiver placebo effect is typically evident. However, little is known about effect sizes...

  • The Systemic Safety of Bromfenac Ophthalmic Solution 0.09%. Stewart, Robert H.; Grillone, Lisa R.; Shiffman, Mitchell L.; Donnenfeld, Eric D.; Gow, James A. // Journal of Ocular Pharmacology & Therapeutics;Dec2007, Vol. 23 Issue 6, p601 

    Study Objective: The aim of this study was to evaluate the systemic safety of a commercially available bromfenac ophthalmic solution 0.09% for the treatment of postoperative inflammation and reduction of ocular pain in subjects who have undergone cataract extraction. Design: Two phase III,...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics